Dr Taylor graduated in 1998 with a PhD in molecular virology from the University of Warwick, UK. After working in a frontline viral diagnostic laboratory he joined the University of Birmingham in 2000 to work on Epstein-Barr virus. Dr Taylor's research on EBV has focussed on the T-cell response to virally-encoded antigens with particular focus on the subset of viral antigens expressed in the malignant cells of the various EBV-associated cancers which together comprise 1.5% of all cancers globally. Dr Taylor led the development of the world's first therapeutic EBV vaccine designed to elicit CD8 and CD4 T-cell responses to these antigens, taking the vaccine through first-in-human Phase Ia trials in the UK and Hong Kong and subsequent Phase Ib and Phase II trials. Dr Taylor's work on the vaccine was recognised in 2015 with the award to him and the vaccine team of the prestigious Cancer Research UK NCRI Translational Research Prize.